Moderna to receive up to $160 million in upfront and near-term development and regulatory milestones, in addition to commercial and sales milestones and tiered royalties on net sales CAMBRIDGE, MA / ...
mRNA-3927 is a strong strategic fit with Recordati’s rare Metabolic portfolio Collaboration combines Moderna’s expertise in mRNA technology for rare metabolic disorders with Recordati’s established ...
Collaboration combines Moderna’s expertise in mRNA technology for rare metabolic disorders with Recordati’s established global rare disease commercial infrastructure Moderna will continue to lead ...
NEW YORK – Moderna on Thursday said it has struck a deal with Recordati, under which the Italian pharmaceutical company will commercialize Moderna's investigational mRNA drug for propionic acidemia, ...
Moderna will continue to lead clinical development and manufacturing for mRNA-3927 Moderna to receive up to $160 million in upfront and near-term development and regulatory milestones, in addition to ...
Moderna to receive up to $160 million in upfront and near-term development and regulatory milestones, in addition to commercial and sales milestones and tiered royalties on net sales "We are proud to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results